Related Experiment Video
Updated: Aug 5, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Chemotherapy on Harding-Passey melanoma with gladenine. Part I
Growth
|June 1, 1976
Summary
Gladenine, an antibiotic from Paecilomyces todicus, showed efficacy against Harding-Passey melanoma. Combining Gladenine with low-dose Hydrazine sulfate significantly increased tumor-free survival in mice.
Area of Science:
- Oncology
- Microbiology
- Pharmacology
Background:
- Harding-Passey melanoma is a model for studying tumor response.
- Gladenine is an oncolytic antibiotic derived from the novel fungus Paecilomyces todicus.
- Investigating novel therapeutic agents for melanoma is crucial.
Purpose of the Study:
- To evaluate the efficacy of Gladenine as a single agent against Harding-Passey melanoma.
- To assess the synergistic effects of Gladenine combined with Hydrazine sulfate in a murine melanoma model.
- To determine optimal dosage and treatment duration for Gladenine-based therapies.
Main Methods:
- A long-term screening technique was employed using Harding-Passey melanoma in mice.
- Mice received intraperitoneal injections of Gladenine (15 mg/100 gm wt/mouse) for 18-34 days.
- Combined therapy involved Gladenine with varying doses of Hydrazine sulfate (1.5 mg or 2.5 mg/100 gm wt/mouse).
Main Results:
- Gladenine monotherapy resulted in tumor absence in approximately 33% of mice (T/C = 0.16).
- Combination therapy with Gladenine and low-dose Hydrazine sulfate (1.5 or 2.5 mg) achieved 60-100% tumor-free mice, maintained long-term.
- Higher doses of Hydrazine sulfate (3.75 mg) in combination therapy yielded less favorable outcomes.
Conclusions:
- Harding-Passey melanoma exhibits susceptibility to Gladenine chemotherapy.
- Low-dose combination therapy of Gladenine and Hydrazine sulfate demonstrates significant synergistic anti-melanoma activity.
- Further research into Gladenine and its combination therapies holds promise for melanoma treatment.
